Biotech Stock Alert: SUNSHINE BIOPHARMA (OTCBB:SBFM) TAKES DELIVERY OF NEWLY MANUFACTURED BATCH OF Adva-27a AND PROCEEDS TO CONDUCTING BI0LOGICAL VERIFICATION OF THE COMPOUND'S ANTI-CANCER ACTIVITY

Montreal, Quebec, Canada - September 4, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has taken delivery of an initial batch of Adva-27a from the Contract Manufacturing Organization (CMO) and has proceeded to conducting a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity. Among the tests we will be performing are Topoisomerase II inhibition assays and cytotoxicity evaluations. The Topoisomerase II inhibition tests are already underway and the cytotoxicity evaluations will be initiated later this week. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

"We are delighted to have advanced to this stage in our Adva-27a development program", said Dr. Steve N. Slilaty, Sunshine’s President and CEO. “Biological testing is an important quality control procedure to ensure batch to batch identity in the manufacturing process”, he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at the Investorideas.com newswire
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tech Stock Q&A: CEO of WRAPmail (OTC: WRAP) Shares his Vision of Changing the Face of Email Marketing

Tech Stock Q&A: CEO of WRAPmail (OTC: WRAP) Shares his Vision of Changing the Face of Email Marketing




New York, New York –August 28 2012 – (www.investorideas.com newswire, ) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors, including tech stocks, issues an exclusive Q&A interview with the C.E.O of WRAPmail, Inc. (OTC:WRAP).



The WRAPmail email template system adds a dynamic, interactive and trackable letterhead to the regular emails sent daily.



Mr. Rolv E. Heggenhougen, CEO discusses how WRAPmai is helping small to large businesses build and expand their online brands and the opportunity that represents for his Company.



Q: Investorideas.com staff

Rolv can you explain in simple terms to investors how WRAPmail works and what differentiates it in the marketplace?





A: Rolv E. Heggenhougen, CEO

The concept behind WRAPmail (WRAP) is to utilize the facts that almost everyone have websites, social network site(s) and also send emails every day. WRAPmail’s main focus is to turn every one of these into marketing and branding.





Q: Investorideas.com staff

Can you give investors insight into some of your recent customers and clients that have signed on to use WRAPmail?



A: Rolv E. Heggenhougen, CEO

We have signed over 6,000 clients from all corners of the world and most industries. The most recognizable names are probably Toshiba, Verizon and RE/MAX. We sign new clients every day for our various solutions.



Q: Investorideas.com staff

Can you explain the revenue models within the Company and where you are seeing the biggest growth opportunity?



A: Rolv E. Heggenhougen, CEO

WRAPmail has a 3-prong revenue model and believe the greatest growth opportunity lays in 3rd party ads in free users emails:

1. License revenue from paid clients

2. Advertising revenue from 3rd party ads

3. Affiliate revenue from Super affiliates

Q: Investorideas.com staff

What are your key technology advantages?



A: Rolv E. Heggenhougen, CEO

Interestingly enough there is no other company with a similar solution out there. Most “email marketing companies” focus solely on mass emails where our main focus is the regular emails we all send every day. Main advantages: easy to make WRAPS, easy to send WRAPPED emails AND they arrive in Outlook and Notes for example WITHOUT the RED X that we always see from the mass email systems (i.e. no need to “right click and download images”).

Q: Investorideas.com staff

According to your filings you and other senior management have recently purchased stock in the open market. Can you give investors some insight as to the recent transactions?



A: Rolv E. Heggenhougen, CEO

We believe in the company and obviously think the stock prices we bought at were attractive. Neither the CEO nor CTO are taking any salary.



Q: Investorideas.com staff

In closing, can your plan to grow revenue both short term and long term, as referenced in your recent August 15th press release?



A: Rolv E. Heggenhougen, CEO



We have announced that we signed a Term Sheet for $1M and this is crucial for us to drive marketing, technology and management. We also just started posting quite a few job opportunities on our site and hope to hire qualified staff to help grow our sales. The opportunity is enormous and only a 1% market share would turn us into a very large company in terms of revenues. We are also focusing on Business Development and aim to partner with companies that can help grow our user base.



About WRAPmail (OTC: WRAP) http://www.wrapmail.com/



The concept behind WRAPmail (WRAP) is to utilize the facts that almost everyone have websites, social network site(s) and also send emails every day. These emails can become complete marketing tools and help promote, brand, sell and cross-sell in addition to drive traffic to the website and conduct research. WRAPmail is available for free (with 3rd party ads) or for a small license fee at www.wrapmail.com. No routines change as users simply download a toolbar or routes emails via Google or WRAPmail's servers.



WRAPmail is a Google Apps Vendor and also compatible with Google Analytics and Google Chrome/Gmail.

More: http://www.otcmarkets.com/stock/WRAP/filings



Social Media:

http://www.facebook.com/wrapmail

https://twitter.com/WRAPmailInc



RE/MAX sample:





Toshiba sample







Verizon sample



WRAPmail Investor Relations:

ir@WRAPmail.com

Phone: (954) 591-8742

Forward looking statements and risks and uncertainties

Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. For more complete information regarding our business and financial condition, you may access our filings at otcmarkets.com. The matters discussed in this press release should not be construed in any matter, shape or form as indicative of the future value of the Company's common stock or its future financial condition.



About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com





Sign up for the free investor news and stock alerts on tech stocks and more http://www.investorideas.com/Resources/Newsletter.asp



Disclaimer for Investorideas.com newswire and related syndication sites : The following news is paid for as disclosed further in this email and /or published as free news content for information only for our readers.Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information tools to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure specifics: Investorideas and related sites have been compensated by WRAP: three thousand five hundred for one week of news and content publication and distribution.

All original content is created from public documents, SEC filings or related regulatory bodies for the exchange, Yahoo Finance, and or the company’s website or management. ALL INVESTMENT INVOLVES RISK AND POSSIBLE LOSS OF ALL INVESTMENT. Please read our social media and related disclaimers at our disclaimer page .Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. If you have any questions regarding information in this press release please contact the company listed in the press release



Contact Investorideas.com: 800 665 0411

Tech Stock Investor News Alert : WRAPmail (WRAP) Signs SpinCUBE as latest Enterprise client

Tech Stock Investor News Alert : WRAPmail (WRAP) Signs SpinCUBE as latest Enterprise client



Cloud Technology Company to use WRAPmail


FORT LAUDERDALE, Fla., Aug. 27, 2012 (www.investorideas.com newswire ) -- WRAPmail, Inc. (OTC:WRAP) has just signed SpinCUBE as its latest Enterprise client.



Rolv E. Heggenhougen, CEO states that, "We are happy to add SpinCUBE to our list of Enterprise clients, particularly as they operate in the tech/cloud arena."



Gregory Geco, Chief Sales Officer for SpinCUBE says, "We have not found anything like what WRAPmail offers anywhere and will start using this amazing tool not only to turn every regular email into branding but also send all our email campaigns through their system." And he continues, "There are too many positives to list but their technology allowing images to be embedded and showing without anyone having to download them is a huge plus. The click tracking we also love, in particular that they offer this in real time!"



About SpinCUBE



SpinCUBE took the traditional Managed Service Provider (MSP) model and revolutionized it. SpinCUBE is a Next Generation MSP. The SpinCUBE executive team has over 85 years of combined experience within all facets of Information Technology. It was this experience that allowed for the mission and vision of SpinCUBE to become a reality. Our goal from inception was to truly provide an end to end solution for our clients that would not only provide an exceptional Virtual Desktop Infrastructure (VDI) experience but also completely alleviate the headache and expense of managing an IT department. SpinCUBE's commitment to our clients and the needs that the ever changing IT world places on them is a responsibility that we take very seriously.



About WRAPmail (OTC: WRAP) http://www.wrapmail.com/



The concept behind WRAPmail (WRAP) is to utilize the facts that almost everyone have websites, social network site(s) and also send emails every day. These emails can become complete marketing tools and help promote, brand, sell and cross-sell in addition to drive traffic to the website and conduct research. WRAPmail is available for free (with 3rd party ads) or for a small license fee at www.wrapmail.com. No routines change as users simply download a toolbar or routes emails via Google or WRAPmail's servers.



WRAPmail also helps search for missing children with every email sent by free users incorporating an RSS feed from the Center for Missing and Exploited Children – see http://www.huffingtonpost.com/rolv-e-heggenhougen/finding-missing-children_b_1540866.html



More info on OTCmarkets.com





About WRAPmail:



Revenues and Revenue models:



We reported for Q1 that we have moved from a free service to a three-prong revenue model:



•WRAPmail PRO: 3rd party advertising revenue from WRAPmail's own advertising network and partner network(s). WRAPmail is the only company in the world that offers 3rd party advertising in regular emails.

•WRAPmail PRO+ and WRAPmail Enterprise: License revenue

•WRAPmail Super Affiliate program revenue

About 300 billion emails are sent everyday world-wide. We conservatively estimate that 90% of these are SPAM or Bulk emails leaving a potential market for WRAPmail of about 30 billion daily one-on-one emails. All free users emails contain a minimum of six 3rd party advertisements. Users who do not want 3rd party ads pay a license fee for PRO+ of $50/user/year.



New clients:



WRAPmail had over 1,000 new PRO and PRO+ signups in the first half of 2012 and also have signed 3 Enterprise clients so far in 2012: RE/MAX KY, Wall-Street.com and The Automotive Resource Network.



New technology and design:



WRAPmail has released quite a few new solutions and designs so far in 2012 with the main focus being ease of use and simplicity.



We have also been very successful in our PR efforts and specifically want to mention the article published in the Huffington Post about how WRAPmail helps in the search for missing children.



WRAPmail Solutions:



1. WRAPmail PRO: Free solution with 3rd party ads.



2. WRAPmail PRO+: Shared solution, $50/user/year, no 3rd party ads.



3. WRAPmail Enterprise: Dedicated solution, $3,500/year plus $40/year per user.



Premade WRAPS:



More than 200 premade templates are currently available for major Network Marketing/Affiliate Marketing/MLM companies, Real Estate Agents, Business, Scenery, Sports, Holidays and Animals with Social Network Interface and personalization (image, text and links).



Clients can also make 100% custom WRAPS in the WRAPmail dashboard using the WRAPmaker.



Advertising Network:



WRAPmail has its own advertising network where users can advertise in other user's emails. The concept is a mix between similar models from Facebook and Google but the difference is our focus is email and not websites. An advertiser can have a free account and there's no usage requirement to become an advertiser. Advertisers simply create their ad in the WRAPmail Dashboard; pick City, State, Country and/or Industry of other users for placement of ads. WRAPmail also has a partnership with Market Leverage for utilization of their advertising inventory.



Affiliate Programs – "Make money with every email you send anyway"



Any user can sign up for one of our affiliate programs and earn up to 25% lifetime commission. Commissions are earned on any business delivered to us by the affiliate but the main focus is to share the 3rd party advertising revenue generated from the regular emails sent by our users.



Google:



WRAPmail is a Google Apps Vendor and also compatible with Google Analytics and Google Chrome/Gmail.



Forward looking statements and risks and uncertainties



Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. For more complete information regarding our business and financial condition, you may access our filings at otcmarkets.com. The matters discussed in this press release should not be construed in any matter, shape or form as indicative of the future value of the Company's common stock or its future financial condition.



WRAPmail Investor Relations:

ir@WRAPmail.com

Phone: (954) 591-8742





Published at the Investor Ideas Newswire



Sign up for the free investor news and stock alerts on tech stocks

http://www.investorideas.com/Resources/Newsletter.asp







Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Investorideas.com and its affiliate sites have been compensated four thousand for one week of news and content distribution and publishing.

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Investorideas.com adds Beverage Stocks Directory to Members List of Stock Directories

New York, New York - August 23, 2012 (Investorideas.com Newswire, www.beveragestocks.com) - Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors reports it has added the beverage stocks directory to the growing list of stock directories for Investor Ideas members.

Investorideas.com stock directories are the most comprehensive online for independent investors. The current list of 14 directories includes stocks on the TSX, OTC, NASDAQ, NYSE as well as global stock exchanges. Current directories include Renewable Energy Stocks Directory, (Over 1300 stocks), Mining and Gold Stocks Directory (over 1400 stocks), Water Stocks Directory, Coal Stocks Directory, Environment/Lohas Stocks Directory, Biotech Stocks Directory, Fuel Cell Stocks Directory, Nanotechnology Stocks Directory, Natural Gas Stocks Directory, Defense Stocks Directory, Oil and Gas Stocks Directory, Agriculture Stocks Directory, China Stocks Directory and the Beverage Stocks Directory. As an added bonus it also includes cloud computing stocks directory and a social networking stocks directory.
The beverage stocks directory can be previewed here
http://www.investorideas.com/Beverage_Stocks/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript

SAN DIEGO - August 23, 2012 (Investorideas.com newswire) - Biodfense stock news;Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Wall Street Transcript has conducted an interview with its Chairman and CEO, Jim Joyce. The full interview is now available to be accessed online at: http://aethlonmedical. investorroom.com/ index.php?s=19.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biodefense Stock News; PositiveID Corporation (OTCBB: PSID) Provides Mid-Year Update to Stockholders

DELRAY BEACH, Fla. - August 23, 2012 - (Investorideas.com Newswire) PositiveID Corporation (OTCBB: PSID) ("PositiveID" or "Company"), an emerging growth company and developer of sophisticated airborne bio-threat detection systems for America's homeland security, today announced a mid-year update and the significant progress it has made realigning its business with a focus on its molecular diagnostics platform. The Company also continues to make strong progress in the diabetes management segment of its business.

Highlights for first half of 2012

• Successfully tested M-BAND, recently featured in Bloomberg Businessweek, to detect five organisms on the CDC's Select Agents list, a requirement for BioWatch
• Added chief technology advisor and biodefense expert, Dr. Kimothy Smith
• Collaborated with the University of Nevada to produce irradiated samples for the development of a biodosimetry cartridge for measuring radiation exposure
• Awarded U.S. Patent for first-of-its-kind Dragonfly detection system for molecular biological diagnostics. Dragonfly is the Company's system that uses disposable microfluidic cartridges for biological sample processing and detection
• Partnered with the Diabetes Research Institute at the University of Miami and Schneider Children's Medical Center of Israel to support the development of the Company's diabetes management products, including Easy Check(TM) and GlucoChip(TM)
• Commenced clinical study of PositiveID's Easy Check, a non-invasive breath glucose detection device, at Schneider Children's Medical Center of Israel under the leadership of world-renowned endocrinologist Prof. Moshe Phillip
• Won gold award at Connected World Value Chain Awards for its iglucose system for diabetes management

Goals for second half of 2012:

• Enter into strategic partnerships and/or teaming agreements with large government contractors for M-BAND manufacturing and system integration for BioWatch Gen-3
• Submit proposal upon release of the final BioWatch Gen 3 RFP, currently scheduled for release in the fourth quarter of calendar 2012, from Department of Homeland Security for the $3.1 billion BioWatch Gen-3 procurement
• Commence second stage of Easy Check clinical study at Schneider Children's Medical Center in Israel
• Complete bench-top unit of GlucoChip glucose-sensor and initiate strategic partnerships
• Continue development of Dragonfly Rapid MDx Cartridge-based diagnostic system for point-of-care diagnostics
• Complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization
• Complete strategic financing to capitalize the Company to execute on these opportunities

William J. Caragol, Chairman and CEO of PositiveID, stated, "We continue to focus on our molecular diagnostic business and are excited about the significant opportunities that lie ahead, including BioWatch Gen 3 and the continued development of our innovative Dragonfly system. We are very proud of our accomplishments year to date and will continue to execute our plan, described above. We believe that we are well positioned to capitalize on the BioWatch Gen 3 opportunity and to make meaningful steps in the commercialization of our diabetes management products. That progress, in conjunction with a strategic financing to fully capitalize the Company, we believe, will allow us to unlock value for stockholders."
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that it has made significant progress realigning its business with a focus on its molecular diagnostics platform; the likelihood that the Company also continues to make strong progress in the diabetes management segment of its business; the likelihood that the Company will enter into strategic partnerships and/or teaming agreements with large government contractors for M-BAND manufacturing and system integration for BioWatch Gen-3; the likelihood that the Company will submit a proposal upon release of the final BioWatch Gen 3 RFP, currently scheduled for release in the fourth quarter of calendar 2012, from Department of Homeland Security for the $3.1 billion BioWatch Gen-3 procurement; the likelihood that the Company will commence the second stage of Easy Check clinical study at Schneider Children's Medical Center in Israel; the likelihood that the Company will complete a bench-top unit of the GlucoChip glucose-sensor and initiate strategic partnerships; the likelihood that the Company will continue development of its Dragonfly Rapid MDx Cartridge-based diagnostic system for point-of-care diagnostics; the likelihood that the Company will complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization; the likelihood that the Company will complete a strategic financing to capitalize the Company to execute on these opportunities; the likelihood that significant opportunities that lie ahead, including BioWatch Gen 3 and the continued development of the Company's innovative Dragonfly system; the likelihood that the Company will continue to execute its plan, described above; the likelihood that the Company is well positioned to capitalize on the BioWatch Gen 3 opportunity and to make meaningful steps in the commercialization of our diabetes management products; the likelihood that that progress, in conjunction with a strategic financing to fully capitalize the Company, will allow the Company to unlock value for stockholders; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize its M-BAND system and Dragonfly system, as well as its diabetes management products; the Company's ability to complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization; the Company's ability to attract strategic partners; the Company's ability to complete a strategic financing; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on August 20, 2012, May 14, 2012, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Gaming Stocks Trading Alert: TechFaith (NASDAQ: CNTF) Moves on News of Launch Mobile Games on China Mobile and China Telecom

New York, NY - August 22, 2012 (Investorideas.com newswire, www.gaminingindustrystocks.com) Investorideas.com staff: Investor Ideas, a global investor research portal for independent investors, specializing in sector research including gaming stocks and China stocks, issues a news and trading alert for China TechFaith Wireless Communication Technology Limited (NASDAQ: CNTF). The stock is trading at $1.18, up 0.05 (4.42%) 1:06PM on over 290,000 shares, with a high of $1.27.
The Company announced news it has gained approval to launch its 17VEE mobile games on China Mobile (0941.HK) and China Telecom (0728.HK), which have 670 million and 141 million, wireless subscribers in China, respectively.
About TechFaith
TechFaith (CNTF) has three primary businesses. Under the TechFaith umbrella, the Company is a leading global mobile solutions provider for the global mobile handsets market (previously called the ODP (Original Developed Product) business)). Under its TecFace brand, the Company is a leading developer of specialized mobile phones for differentiated market segments, including the rapidly growing smartphone market targeting wireless mobile phone network operators and end users; the Company also serves sports enthusiasts with a tailored line under the Jungle brand and the teen market under licensed brands. Under the Company's 17VEE brand, the Company has built a leading intellectual property based motion gaming business ranging from Bluetooth-enabled motion gaming controllers and software to a planned proprietary set-top motion game box. For more information, please visit www.techfaithwireless.com, www.17vee.com and www.798game.com.

Follow and research gaming stocks at the gaming stocks directory
http://www.investorideas.com/ GIS/ Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts. Sectors include biotech stocks, tech stocks, beverage stocks, mining stocks, water, renewable energy, oil and gas.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Q&A with Healthcare Stock Comprehensive Care (OTCBB: CHCR)

New York, NY - August 22, 2012 (Investorideas.com newswire) Investorideas.com, a leader in sector research for independent investors including healthcare and biotech stocks features an exclusive interview with Mr. Clark A. Marcus, Chairman and CEO of Comprehensive Care Corporation (OTCBB: CHCR). CHCR is a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S.

Q: Investorideas.com staff
For new investors can you give an overview of the Company services and where you have locations?
A: Clark Marcus, Chairman and CEO
We provide managed behavioral healthcare, substance abuse, and pharmacy management services. We provide these services primarily to commercial, Medicare, Medicaid and Children's Health Insurance Program ("CHIP") health plans. Additionally we provide pharmacy and analytic services for our health plan clients to integrate medical claims data and pharmacy data into actionable information so patient care can be coordinated cost effectively. Our managed care operations include at-risk behavioral health contracts, at-risk pharmacy management contracts, and administrative service agreements.
We have also recently launched a cost containment pharmacy management program designed to lower our clients total annual pharmacy spend by at least 10%. Under this unique and innovative program for the industry, we will enter into at-risk pharmacy management agreements whereby we guarantee our client's savings over their previous year's pharmacy spend.
We service clients in 22 states, the District of Columbia and Puerto Rico, with primary offices/facilities located in Tampa, Florida and San Juan, Puerto Rico.
Q: Investorideas.com staff
In terms of payments for patient care can you give us an idea of how you are compensated and if the recent and pending changes in healthcare in the US will impact your company moving forward?
A: Clark Marcus, Chairman and CEO
We typically enter into contracts on an annual basis, which evergreen every one or two years. Our arrangements with our clients fall into two broad categories:

• At-risk arrangements under which our clients pay us a fixed fee per member per month in exchange for our assumption of the financial risk of providing behavioral health and/or pharmacy management services; and
• ASO arrangements where we manage behavioral healthcare programs or perform various managed care services, such as clinical care management, provider network development, and claims processing without assuming financial risk for member behavioral healthcare costs.

We believe the recent pending changes in healthcare in the US are beneficial to our business since the number of people that will be included under government mandated programs will increase materially. Our existing business primarily services government mandated programs through our health plan clients.
Q: Investorideas.com staff
Your Company recently reported six month results for 2012 that are impressive for a small OTC Company. Can you give investors a snapshot of the results?
A: Clark Marcus, Chairman and CEO
For the first time in many years, we have been profitable for two consecutive quarters.
In the second quarter, ended June 30, 2012, we earned $1.6 million while losing almost $4 million in the comparable quarter last year. Revenues for the quarter reached $18.2 million, compared with $18.6 million in the same period of 2011, or a slight decrease of less than 2%.
Several new profitable contracts in the behavioral healthcare segment, a strict cost containment program and a contract amendment with a major Puerto Rican client all contributed to this substantial improvement.
Additionally, our recently launched innovative pharmacy cost containment program, which is able to reduce pharmacy costs for our healthcare customers by up to 10%, is expected to start generating revenues in a few months. Considerable growth is expected from this program in the following years.
Q: Investorideas.com staff
How does your Company fill the gap in current services for your sector and where do you see the future growth?
A: Clark Marcus, Chairman and CEO
Our pharmacy management contracts were up 18.9 percent, or $3.1 million, to $19.4 million in the first six months of 2012. Our strategies to reduce pharmaceutical costs for our clients will be a key element for our future growth.
Thus far, all of our substantial growth over the past two years has been organic in nature. However, it should not be a surprise if we started searching for some nice acquisitions.
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com .
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the success and profitability of the new pharmacy initiatives, our ability to reduce pharmaceutical costs by up to 10% for our clients under the new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan to generate exponential growth,  the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts. Sectors include biotech stocks, tech stocks, beverage stocks, mining stocks, water, renewable energy, oil and gas.
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp/ Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source: Investorideas.com/ CHCR
Contact Investorideas.com 800 665 0411

Mining and Silver Stock News: SilverCrest (TSX.V: SVL) Announces Trading on NYSE MKT to Commence August 27, 2012

VANCOUVER, BRITISH COLUMBIA - August 22, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX-V:SVL)(OTCQX:STVZF) (the "Company") is pleased to announce that its common shares have been authorized for listing on the NYSE MKT in New York. The shares will begin trading on the NYSE MKT on August 27, 2012 under the trading symbol "SVLC". The Company's common shares will continue to be listed on the TSX Venture Exchange under the trading symbol "SVL".

"This NYSE MKT listing represents another significant milestone in SilverCrest's growth," stated J. Scott Drever, SilverCrest's President. "The listing is expected to provide greater trading accessibility for investors in the United States and internationally."
SilverCrest Mines Inc. (SVL.V) operates in Mexico and is a low cost precious metals producer with its headquarters based in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, which is located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango, Mexico.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
Disclaimer: Investorideas.com does not make stock recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Silvercrest Mines has compensated Investorideas for annual news publication and distribution and company profile: nine thousand seven hundred starting August 2012
More info: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Solar Stocks on the Move: FSLR, SOL, YGE

New York, NY - August 21, 2012 (Investorideas.com newswire renewable energy/ green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for solar stocks trading August 21st.
First Solar, Inc. (NasdaqGS :FSLR) is trading up at $24.00, up $1.54 or 6.87% as of 2:19PM on just under 12 Million shares.
ReneSola Ltd. (NYSE :SOL) is trading up 4.57%, trading at $1.83,up 0.08 as of 2:15PM EDT on over 500,000 shares.
Yingli Green Energy Holding Co. Ltd. (NYSE :YGE) is trading up at $2.08, gaining 0.12 of 6.12% as of 2:20PM EDT on just over 1.2 Million shares . The stock had a day high of $2.14.
Several of the smaller OTC and TSX solar stock have also had gains today including Sustainable Energy Technologies (STG.V), up 11%.
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Research more solar stocks on global stock exchanges - and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

OTCBB Tuesday Morning Movers; Beverage Stocks (OTCBB: ATTD), (OTCBB: AHFD) Make Top Volume Leaders List

New York, New York - August 21, 2012 (Investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors reports on the top five volume traders on the OTCBB for Tuesday morning, August 21st.

Beverage stocks Attitude Drinks Inc (OTCBB: ATTD) and Active Health Foods Inc. (OTCBB: AHFD) make the list again, showing investor interest in microcap beverage stocks continues to remain high.
Mass Hysteria Entertainment Company Inc. (OTCBB: MHYS) leads the OTCBB volume leadears trading in a range of 0.0009 - 0.0010 on over 11 Million shares. Last week it reported it entered into a non-binding Memorandum of Understanding to acquire a real estate investment/development group which owns properties consisting of a 16 unit rental apartment building with adjacent land with planned use for a second apartment building and 12.4 acres of land for development located adjacent to a key highway intersection both located in Southern California.
Beverage stock Attitude Drinks Inc (OTCBB: ATTD) has traded over 9 Million shares at the time of this report. The stock has made the top volume leaders list frequently in the past few weeks.
Applied DNA Sciences Inc. (OTCBB: APDN) is down on over 6 Million shares following its run in the past few days. The stock had a morning range of $0.12 - 0.1595.
Beverage and health stock Active Health Foods Inc. (OTCBB: AHFD ) is up over 4% on just under 5 Million shares. This stock also makes the top volume leaders list frequently.
Internal Fixation Systems Inc. (OTCBB: IFIX) is trading down this morning on just under 3 Million shares.
About OTCBB
http://www.otcbb.com/
Research beverage stocks with the beverage stocks directory at Investorideas.com
http://www.investorideas.com/Beverage_Stocks/Stock_List.asp
Featured Beverage Stock
DC Brands International (OTC: HRDN) specializes in the manufacturing of its functional beverages and health products. Established in 1998, DC Brands began producing a number of lines of energy drinks in 2005. DC Brands then purchased the assets of H.A.R.D. Nutrition and began its quest to produce a new health line of products. DC Brands has recently announced the release of its new H.A.R.D. Nutrition Functional Water Systems, which it expects will revolutionize the functional beverage category.
In June Mr. Stephen Horgan, Brand Aspirations Founder and Former Coca-Cola (NYSE:KO) and Coors Veteran purchased controlling interest of DC Brands International, Inc. (OTC: HRDN) /dba/H.A.R.D. Nutrition and is now acting President and CEO of the Company.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
DC Brands is featured on Running Bull OTC for SMS alerts - Sign up now!
http://www.runningbullotc.com/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com and its SMS partner Running Bull OTC have been compensated by HRDN for one month of news, email and sms: twenty five thousand
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411

Biotech Stock News Alert; Aethlon Medical (OTCBB: AEMD) Announces Renewal of DARPA Dialysis-Like Therapeutics Contract

SAN DIEGO - August 21, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projects Agency (DARPA) has exercised an option agreement to proceed with year-two of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.

As a result, Aethlon is able to initiate work toward year-two contract milestones ahead of the schedule. The second year of Aethlon's DLT contract contains eight milestones representing a potential of $1,617,446 in revenue opportunity. To date, Aethlon has invoiced $1,758,300 to DARPA for achieving seven of eight milestone objectives targeted in year-one of the DLT program. Aethlon further disclosed that it has completed its eighth year-one milestone objective worth $216,747, but has not yet invoiced DARPA.
The Company also disclosed that it has teamed with two larger organizations in response to a follow-on DLT contract opportunity entitled DARPA BAA-12-36. The announcement of DARPA BAA-12-36 contract awards is anticipated later this fall.
The goal of the DLT program is to develop a portable device that removes "dirty" blood from the body, separates harmful agents, and returns "clean" blood to the body in a manner similar to dialysis treatment of kidney failure. The resulting device would decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States annually. In the DLT program, Aethlon has been contracted to utilize the Aethlon ADAPT™ system to create an extracorporeal blood purification cartridge that selectively eliminates sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The Aethlon ADAPT™ converges advanced plasma membrane technology with high affinity drug agents to allow the selective yet rapid clearance of disease targets from the entire circulatory system without damaging blood cells or removing particles essential for health. Aethlon has also been contracted to develop a novel blood circulatory instrument that will deliver ADAPT™ based and other therapeutic filtration devices without systemic anticoagulants normally required in extracorporeal therapies.
Beyond the civilian need for anti-sepsis therapies, the device proposed in the DLT program would play an important role in saving the lives of wounded U.S. military personnel, as infection leading to sepsis is a significant cause of mortality. When sepsis is complicated by shock, approximately half of patients do not survive for 30 days, even if effective antibiotics are used. Unfortunately, the fatality rate from sepsis can be high, given that antibiotic-resistant bacteria are an increasing problem for injured warfighters and military treatment facilities. Bio-agents engineered for resistance against antibiotics also represent a significant threat to both warfighters and citizens. Current culture-based methods of identifying blood-borne pathogens can take 48 hours or longer to identify the offending pathogen, and some blood-borne pathogens do not propagate in culture. Pending these culture results, septic patients are treated with protocol-based broad-spectrum antibiotics. In the event the offending pathogen is resistant to the empirically chosen antibiotic, the fatality rate may increase as much as 9% per hour.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Healthcare Stock News: Comprehensive Care Corporation (OTCBB: CHCR) Names Jairo Estrada Senior Management Advisor To Assist in Growing the Company's New Pharmacy Initiatives

TAMPA, Fla. - August 20, 2012 (Investorideas.com newswire) Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), which provides behavioral health, substance abuse and psychotropic pharmacy management services, is pleased to announce that it has appointed Jairo A. Estrada, who was instrumental in growing a gardening and yard care company from $7 million to $400 million. Mr. Estrada will advise senior management in implementing a plan designed to increase the Company's revenue and assist in the marketing of its innovative pharmacy cost-containment program.

Clark A. Marcus, Chairman and CEO said, "On behalf of senior management, I would like to express how excited and pleased we are to add Mr. Estrada, a highly regarded senior executive, to the CompCare team. Mr. Estrada's career achievements are nothing short of remarkable. We believe his business acumen and proven capabilities in generating substantial corporate growth will be of great benefit to the Company. I look forward to the Company's continued progression with the help of Mr. Estrada's knowledge and guidance."
Mr. Estrada was named President and Chief Operating officer of Garden Way Inc. in 1984 and subsequently became Chairman and CEO. The Company produced and marketed a wide range of well known outdoor power equipment, including the TROY-BILT® Roto Tiller and the BOLENS® Tractor. He assisted in developing a multi-channel distribution system to increase company revenues.
Mr. Estrada was also instrumental in the acquisition by Garden Way of StairMaster Sports/Medical Products, Inc., a major worldwide designer and manufacturer or therapeutic exercise equipment, and five other businesses, to exponentially increase the company's revenues.
As CEO, Mr. Estrada also guided one of the first U.S. companies to penetrate the Chinese market and sell products in the world's most populous nation. He also serves as Chairman of a manufacturing company servicing the pharmaceutical industry in Puerto Rico.
Mr. Estrada received a Bachelor's Degree in Economics and in Business Administration, and a Master's Degree in Organizational Behavioral Sciences from SUNY at Buffalo, New York. He has served on the Board of Directors of numerous companies, including the leading telecommunications company in Puerto Rico; the Chase Manhattan Bank Board of Directors and its Executive Committee, and Global Crossing.
"In a sector where costs continue to rise, I was intrigued by CompCare's recent pharmaceutical initiative, a service with the potential to significantly reduce costs for corporations, as well as the success Clark Marcus and his team have already accomplished. I am eager to work with CompCare's team and confident that I can contribute to the Company increasing its share of the pharmacy management market and an even greater level of corporate success in its healthcare initiatives," said Mr. Estrada.
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.

Published at Investorideas.com Newswire

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Sunshine Biopharma (OTCBB: SBFM) Management Bets on Lead Anti-Cancer Compound Adva-27a; Taking No Compensation

New York, New York - August 20, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks releases an investor alert on Sunshine Biopharma Inc. (OTCBB: SBFM) reporting on management's unusual commitment to the shareholders; no compensation is currently paid out to the top executives according to Company filings.

Key management including Chairman and CEO, Dr. Steve N. Slilaty Ph.D, Mr. Camille Sebaaly, CFO and Mr. Michele Di Turi, COO do own equity in the company.
Sunshine Biopharma's lead compound, Adva-27a is an effective and highly specific Topoisomerase II (Top2) Inhibitor that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The Company recently reported that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal ( Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
Read Investorideas.com Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
SEC filings: http://finance.yahoo.com/q/sec?s=SBFM+SEC+Filings
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Microcap Beverage Stocks to Watch: (OTC: ATTD), (OTC: BBDA), (OTC: HRDN), (OTC: HBRM)

New York, New York - August 17, 2012 (Investorideas.com Newswire, www.beveragestocks.com) - Investorideas.com, an investor research portal specializing in sector research including beverage stocks issues an alert for actively traded beverage stocks for August 17th.

Herborium Group, Inc. (OTC: HBRM) is up 42.5%, trading at 0.0017 as of 2:15PM EDT. The Company reported news earlier this week “distribution of Kamasutra™ Exotic Vodka with herbal formula provided by Herborium, a pioneering specialty drink now available for the first time in the US, has officially started with a first wholesale order of 1000 cases.”
Bebida Beverage Company (OTCBB: BBDA) is by far one of the most actively traded beverage stocks on the OTC, currently at 0.0170, down 0.0012(6.59%) 2:16PM EDT on over 81 Million shares.
DC Brands International Inc. (OTC: HRDN) is trading down with a day's range of 0.0035 - 0.0043 on over 500,000 shares. The stock has had some big percentage gains in earlier trading this week.
Attitude Drinks Incorporated (OTC BB: ATTD) is flat but trading big volume, currently at $0.0006 as of 2:09PM EDT on over 14.6 Million shares.
Research beverage stocks with the beverage stocks directory at Investorideas.com - one of the largest beverage stock directories online
http://www.investorideas.com/Beverage_Stocks/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
DC Brands is featured on Running Bull OTC for SMS alerts - Sign up now for the Ap - now available for Android and iphone and Blackberry coming soon,
http://www.runningbullotc.com/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com and its SMS partner Running Bull OTC have been compensated by HRDN for one month of news, email and sms: twenty five thousand  
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411